Overview

A Prospective, Multicenter, Phase-II Trial of Ibrutinib Plus Venetoclax in Patients With Creatinine Clearance >= 30 ml/Min Who Have Relapsed or Refractory Chronic Lymphocytic Leukemia (RR-CLL) With or Without TP53 Aberrations

Status:
Active, not recruiting

Trial end date:
2026-01-01

Target enrollment:

Participant gender:

Summary

The aim of the current trial is to evaluate if combination treatment with venetoclax + ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia (RR CLL) can lead to MRD negativity, which may induce long lasting remissions for MRD-negative patients randomized to stopping treatment after 15 induction cycles.

Phase:

Phase 2

Details

Lead Sponsor:

Stichting Hemato-Oncologie voor Volwassenen Nederland

Collaborator:

Nordic CLL Study Group

Treatments:

Venetoclax